The high-fidelity gateway to early MCI cohorts.
Stop losing millions to 88% screen-fail rates. Acurist gives CROs the validated digital infrastructure to accurately triage, enrich, and secure progressive MCI cohorts — before the first PET scan.
For clinical-operations teams, the recruitment funnel is a high-stakes obstacle course. Subjective scales flood the pipeline with false positives — enrolling stable, non-progressive individuals or patients whose impairment stems from reversible conditions. The result: millions wasted on premature Amyloid/Tau PET scans, neuroimaging, and fluid biomarkers for participants who should have been filtered out on day zero.
Low-sensitivity tools push too many ineligible participants into expensive neuropsychological evaluation.
Each false positive consumes site capacity, study coordinator hours, and per-participant budget.
Inefficient pre-screening lengthens recruitment cycles and pushes back read-out timelines.
Variability in how brief screens are administered across sites adds noise to baseline cognitive measures.
Four operational advantages that protect trial budget, timelines, and statistical power.
Brief paper-and-pencil screens like MoCA carry specificity around 54–62% in primary care — meaning a meaningful share of healthy older adults can be flagged with possible MCI. Each false positive can mean a costly downstream workup (PET, CSF, neuropsych) the trial budget didn’t need.
Raw scores on MMSE/MoCA can be warped by education and age — highly educated participants can mask early symptoms (ceiling effect); under-educated participants can score low without true pathology. The MCI Screen compares performance against age- and education-matched peers using a peer-reviewed normative model.
Paper screens demand specialized training and a quiet clinical environment, limiting recruitment to traditional memory centers. The MCI Screen is a standardized, digital assessment that takes under 10 minutes and can be deployed across primary-care referral networks, telehealth visits, or community outreach.
Built on the CERAD Word List Memory subset, the MCI Screen evaluates memory, executive function, judgment, and language — outputting a probability of progressive MCI rather than a flat cutoff. Enrich cohorts with participants tracking toward clinical decline so disease-modifying therapeutics can demonstrate statistical efficacy.
A standardized assessment package, hands-on operational support, and configurable data and compliance infrastructure.
Four independent peer-reviewed studies. Validated across 121,000+ participants in the US and Japan. Published in PNAS, the Journal of Alzheimer’s Disease, the American Journal of Alzheimer’s Disease, and the Journal of Prevention of Alzheimer’s Disease.
Review the clinical evidence →See what high-precision MCI pre-screening saves a cognitive trial — by filtering false positives before they consume expensive Amyloid/Tau PET and biomarker validation. Compare a traditional MoCA/MMSE funnel against the MCI Screen funnel for the same enrollment target.
Drag any slider to model a different specificity scenario. Defaults are anchored to published literature — citations beside each control.
| Screen | Sens. | Your spec. | Published spec. |
|---|---|---|---|
| MCI Screen | 95% | — | 88–97% |
| MoCA | 74–84% | — | ~60% (primary care) |
| MMSE | 71% | — | ~81% (memory clinic) |
Illustrative projection comparing recruitment-funnel cost with traditional brief screens versus the MCI Screen. Biomarker and screening cost bases are built into the model. Results depend on protocol design, indication, and site mix, and are not a guarantee of outcomes or a pricing proposal.
See the side-by-side funnel comparison — referrals, biomarker scans, sunk cost, and total recruitment cost. We’ll email the detailed report to you.
By submitting this form, you agree to our Privacy Policy.
No spam. Your figures are sent to the Acurist partnerships team so we can follow up with a study-specific analysis.
| Recruitment step | Traditional | MCI Screen |
|---|---|---|
| Referrals pre-screened | ||
| Participants enrolled | ||
| Biomarker / PET scans run | ||
| Wasted scans (on screen-fails) | ||
| Digital pre-screening cost | ||
| Wasted biomarker spend | ||
| Total recruitment cost |
Confidential & proprietary illustrative model — not a pricing proposal. For a study-specific analysis tailored to your protocol and indication, contact sales@acurist.ai.
Tell us about your trial and we’ll set up a short, no-pressure conversation about how the MCI Screen fits your recruitment workflow, study design, and enrollment timeline — with a study-specific funnel analysis.
Study-specific funnel analysis · No commitment · We reply within one business day
A short, no-pressure conversation about how the MCI Screen can fit your recruitment workflow, study design, and enrollment timeline — with reproducible endpoints and audit-ready documentation.